Dianthus Therapeutics DNTH Cash Flow Statement
| Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | ||
|---|---|---|---|---|---|---|
| -$40.83M-11.1% | -$36.77M-16.2% | -$31.63M-7.2% | -$29.51M-3.8% | -$28.44M-13.0% | ||
| $32K+18.5% | $27K-10.0% | $30K+11.1% | $27K+3.8% | $26K+4.0% | ||
| $10.6M+83.0% | $5.79M+1.5% | $5.71M+7.4% | $5.32M+35.7% | $3.92M+2.0% | ||
| -$28.86M+5.6% | -$30.56M-27.9% | -$23.89M+13.5% | -$27.63M-0.7% | -$27.44M-29.0% | ||
| $10K+100% | $5K-89.1% | $46K+91.7% | $24K-22.6% | $31K+24.0% | ||
| -$133.97M+33.4% | -$201.28M-861% | $26.45M+78.8% | $14.79M+164% | -$23.11M+91.1% | ||
| $739.41M+169% | $274.51M+48,230% | $568K+253% | $161K-99.6% | $39.68M+13,304% | ||
| $576.58M+1,251% | $42.68M— | —— | -$12.68M-16.5% | -$10.88M+96.1% | ||
| -$28.87M+5.5% | -$30.56M-27.7% | -$23.94M+13.4% | -$27.65M-0.7% | -$27.48M-29.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Dianthus Therapeutics's cash flow data come from?
- Every line is extracted from Dianthus Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.